On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

CRISPR Therapeutics (Switzerland)

InstitutionResearch output, impact & collaborations

CRISPR Therapeutics (Switzerland) is a institution indexed in ScholarIQ from OpenAlex.

What is known about CRISPR Therapeutics (Switzerland)?

ScholarIQrecord summary

CRISPR Therapeutics (Switzerland) is a research organisation in Basel, CH. OpenAlex records 120 works and 10,687 citations for it. 94 researchers list it as their most recent affiliation.

How many works does CRISPR Therapeutics (Switzerland) have?

ScholarIQindexed works

CRISPR Therapeutics (Switzerland) has 120 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for CRISPR Therapeutics (Switzerland) →

How many citations does CRISPR Therapeutics (Switzerland) have?

ScholarIQcitation count

CRISPR Therapeutics (Switzerland) has 10,687 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for CRISPR Therapeutics (Switzerland) →

How many researchers are at CRISPR Therapeutics (Switzerland)?

ScholarIQresearcher count

CRISPR Therapeutics (Switzerland) has 94 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at CRISPR Therapeutics (Switzerland)?

ScholarIQavg h-index

CRISPR Therapeutics (Switzerland) has an average h-index of 5 in OpenAlex.

Open the OpenAlex record →

What is the ROR of CRISPR Therapeutics (Switzerland)?

ScholarIQror

The ROR for CRISPR Therapeutics (Switzerland) is on the source record.

Open the ROR →

What is the OpenAlex record for CRISPR Therapeutics (Switzerland)?

ScholarIQopenalex

The OpenAlex for CRISPR Therapeutics (Switzerland) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind CRISPR Therapeutics (Switzerland)?

ScholarIQtop researchers by citations

Ainsley Ross · Glioma Diagnosis and Treatment

12 works365 citations

What are the most-cited papers on CRISPR Therapeutics (Switzerland)?

ScholarIQmost cited works

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

Andrew D. Norden, Jan Drappatz, Alona Muzikansky, Karly David, Mary Gerard, M. Brenna McNamara, Phuong Phan, Ainsley Ross, Santosh Kesari, Patrick Y. Wen

Journal of Neuro-Oncology. 2008139 Citations

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson

Joshua J. Field, Gene Lin, Maureen Okam, Elaine M. Majerus, Jeffrey R. Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, David G. Nathan

Blood. 2013100 CitationsOPEN ACCESS

Comparative rates of adverse events with different formulations of intravenous iron

Maureen Okam, Elyse Mandell, Nathanael D. Hevelone, Wentz Rachel, Ainsley Ross, Gregory A. Abel

American Journal of Hematology. 201258 CitationsOPEN ACCESS

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul Shaughnessy, Armin Ghobadi, Michael Bishop, Ana Alfonso Piérola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William B. Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant-Cohen, Richard T. Maziarz, Carlos Bachier

Blood. 202257 Citations

Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.

David G. Nathan, Joshua J. Field, Gene Lin, Donna Neuberg, Elaine M. Majerus, Onyinye Onyekwere, Jeffrey R. Keefer, Maureen Okam, Ainsley Ross, Joel Linden

PubMed. 20128 CitationsOPEN ACCESS

How much of the research on CRISPR Therapeutics (Switzerland) is open access?

ScholarIQopen access share

30%OPEN ACCESS

Gold

Green

10%

Hybrid

Bronze

20%

Closed

70%